GW Pharmaceuticals to Present at Upcoming Investor Conferences
February 26, 2019 11:08 ET
|
GW Pharmaceuticals plc
- Leerink Partners 8th Annual Global Healthcare Conference on February 28, 2019 -- Cowen and Company 39th Annual Health Care Conference on March 11, 2019 - LONDON and CARLSBAD, Calif., Feb. 26,...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending 31 December 2018 and Host Conference Call on 26 February 2019
February 07, 2019 15:22 ET
|
GW Pharmaceuticals plc
LONDON, Feb. 07, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel...
GW Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
December 31, 2018 07:00 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Dec. 31, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and...
GW Pharmaceuticals plc Reports Fiscal Fourth Quarter and Year-End 2018 Financial Results and Operational Progress
November 27, 2018 16:00 ET
|
GW Pharmaceuticals plc
- Epidiolex® (cannabidiol) oral solution (CV), first FDA-approved plant-derived cannabinoid medicine launched in the U.S. - - Conference call today at 4:30 p.m. EST - LONDON and CARLSBAD, Calif.,...
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome
November 26, 2018 07:00 ET
|
GW Pharmaceuticals plc
- Primary endpoint achieved with both EPIDIOLEX doses compared to placebo - - Today’s data represents the fourth positive Phase 3 pivotal trial for EPIDIOLEX in Dravet syndrome and Lennox-Gastaut...
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting
November 19, 2018 16:05 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of...
GW Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results and Host Conference Call on 27 November, 2018
November 06, 2018 07:00 ET
|
GW Pharmaceuticals plc
LONDON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel...
EPIDIOLEX® (cannabidiol) Oral Solution – the First FDA-approved Plant-derived Cannabinoid Medicine – Now Available by Prescription in the U.S.
November 01, 2018 06:45 ET
|
GW Pharmaceuticals plc
- Medication indicated for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, two rare, severe childhood-onset epilepsies - - Comprehensive support program...
GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs, Raising Gross Proceeds of $345 Million and Full Exercise of Underwriters' Option to Purchase Additional ADSs
October 05, 2018 10:34 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and...
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million
October 02, 2018 20:04 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and...